TMJ NextGeneration(TM) Feasibility Study

Bruxism Clinical Trial

— Bruxoff  

Official title:

A Feasibility Study of the Bruxoff™ Device to Assess EMG Activity in Subjects Diagnosed With Sleep Bruxism Using TMJ NextGeneration(TM)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02257320
• Other study ID #: TMJ-1002
• Status: Completed
• Phase: N/A
• First received: October 2, 2014
• Last updated: June 8, 2015
• Start date: November 2014
• Est. completion date: May 2015

Study information

• Verified date: June 2015
• Source: Cardiox Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The study is an open-label, prospective, single-center, non-randomized feasibility study of the Bruxoff(TM) device to identify EMG activity associated with bruxism, and to assess the impact of the TMJ NextGeneration(TM) device upon the occurrence of night-time bruxism events and incidence of migraines and headache in subjects diagnosed with sleep bruxism.

Description:

The study will be conducted at one study center in the U.S. Subjects will be enrolled in the trial for a period of 8 weeks. The study will consist of a screening phase lasting up to 2 weeks and a follow up treatment period lasting 8 weeks. Subjects will visit the dental clinic twice during the screening period, then five times during the treatment period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: May 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects at least 18 years of age;

2. Subject has had a diagnosis of sleep bruxism;

3. Subject has been medically screened and diagnosed by a physician as having headaches and/or migraines;

4. Subject is willing to comply with the usage instructions for the Bruxoff device;

5. Is able to read and understand the ICF and has voluntarily provided written informed consent.

6. Subject is able to open their mouth at least 17 mm to be fitted for the TMJ NextGenerationTM device;

7. Male Subjects are willing to have a clean shaven face on the nights that the Bruxoff device will be used;

8. Subject agrees that when using the Bruxoff device to keep their cellular phone in another room.

Exclusion Criteria:

1. Subjects with any physical or behavioral disorder, which, in the opinion of the Principal Investigator, may interfere with the use of the device or compliance with the study protocol;

2. Subject has any sleep disorder other than bruxism;

3. Subjects who have had direct trauma to the jaw;

4. Subjects who have had prior TMJ or ear surgery;

5. Subjects who have a narrow ear canal or impression of the ear canal, which is prolapsed due to an anatomical shift or failure of the ear canal wall structure, or a canal that does not allow for the ear canal second turn to be identified;

6. Subjects with visible or congenital ear deformity as observed on targeted physical exam;

7. Subjects whose ear canal anatomy does not allow for fit of the study device;

8. Subjects who have a history of ear pain unrelated to TMJ;

9. Subjects who have a history of ear drainage in the past 6 months;

10. Subjects who have active ear drainage, swelling, or redness as observed on targeted physical exam;

11. Subject has experienced chronic pain (not including migraine pain) associated with sleep bruxism or TMD for more than six months;

12. Subject has a pacemaker.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bruxism

Intervention

Device:
• TMJ NextGeneration(TM)
The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the ear canal when the jaw is in the open position and permit full passage of sound into each ear. The mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.

Locations

Country	Name	City	State
United States	Ear, Nose and Throat Associates of South Florida	Boca Raton	Florida
United States	Ear, Nose and Throat Associates of South Florida	Boynton Beach	Florida

Sponsors (2)

Lead Sponsor	Collaborator
TMJ Health	Cardiox Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effectiveness of Bruxoff(TM) to measure EMG activity in bruxing subjects using the TMJ NextGeneration(TM) device.		baseline and 8 weeks	No